429 related articles for article (PubMed ID: 20429826)
1. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
Murdande SB; Pikal MJ; Shanker RM; Bogner RH
Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
[TBL] [Abstract][Full Text] [Related]
2. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
[TBL] [Abstract][Full Text] [Related]
3. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
Murdande SB; Pikal MJ; Shanker RM; Bogner RH
J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
[TBL] [Abstract][Full Text] [Related]
4. Refining stability and dissolution rate of amorphous drug formulations.
Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
[TBL] [Abstract][Full Text] [Related]
5. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
Qian F; Huang J; Hussain MA
J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation development.
Mortko CJ; Sheth AR; Variankaval N; Li L; Farrer BT
J Pharm Sci; 2010 Dec; 99(12):4973-81. PubMed ID: 20821397
[TBL] [Abstract][Full Text] [Related]
7. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
Baghel S; Cathcart H; O'Reilly NJ
J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
[TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
9. Deliquescence of pharmaceutical systems.
Mauer LJ; Taylor LS
Pharm Dev Technol; 2010 Dec; 15(6):582-94. PubMed ID: 19895256
[TBL] [Abstract][Full Text] [Related]
10. Solubility Advantage (and Disadvantage) of Pharmaceutical Amorphous Solid Dispersions.
Huang S; Mao C; Williams RO; Yang CY
J Pharm Sci; 2016 Dec; 105(12):3549-3561. PubMed ID: 27692620
[TBL] [Abstract][Full Text] [Related]
11. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
Meng F; Gala U; Chauhan H
Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
[TBL] [Abstract][Full Text] [Related]
12. Emerging trends in the stabilization of amorphous drugs.
Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
[TBL] [Abstract][Full Text] [Related]
13. Co amorphous systems: A product development perspective.
Chavan RB; Thipparaboina R; Kumar D; Shastri NR
Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
[TBL] [Abstract][Full Text] [Related]
14. Using Environment-Sensitive Fluorescent Probes to Characterize Liquid-Liquid Phase Separation in Supersaturated Solutions of Poorly Water Soluble Compounds.
Raina SA; Alonzo DE; Zhang GG; Gao Y; Taylor LS
Pharm Res; 2015 Nov; 32(11):3660-73. PubMed ID: 26123681
[TBL] [Abstract][Full Text] [Related]
15. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
16. Predicting the solubility enhancement of amorphous drugs and related phenomena using basic thermodynamic principles and semi-empirical kinetic models.
Skrdla PJ; Floyd PD; Dell'Orco PC
Int J Pharm; 2019 Aug; 567():118465. PubMed ID: 31279056
[TBL] [Abstract][Full Text] [Related]
17. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
Rodríguez-Spong B; Price CP; Jayasankar A; Matzger AJ; Rodríguez-Hornedo N
Adv Drug Deliv Rev; 2004 Feb; 56(3):241-74. PubMed ID: 14962581
[TBL] [Abstract][Full Text] [Related]
18. Drug polymorphism and dosage form design: a practical perspective.
Singhal D; Curatolo W
Adv Drug Deliv Rev; 2004 Feb; 56(3):335-47. PubMed ID: 14962585
[TBL] [Abstract][Full Text] [Related]
19. Amorphous solid dispersions: a robust platform to address bioavailability challenges.
Newman A; Nagapudi K; Wenslow R
Ther Deliv; 2015 Feb; 6(2):247-61. PubMed ID: 25690090
[TBL] [Abstract][Full Text] [Related]
20. Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery.
Al-Obaidi H; Majumder M; Bari F
Curr Pharm Des; 2017; 23(3):350-361. PubMed ID: 27829335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
